文献速递核素与放射性配体治疗肿瘤 PET/CT

治疗后SPECT/CT对接受[177Lu]Lu-PSMA-617放射配体治疗患者总生存期的预后价值:3项临床试验结果

Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
PubMed 文献 · J Nucl Med · 2025-08-01

研究分析3项临床试验中85例转移性去势抵抗性前列腺癌(mCRPC)患者,评估[177Lu]Lu-PSMA-617治疗后SPECT/CT定量与视觉变化的预后价值。第2周期后SPECT/CT可见新转移灶是总生存期(OS)的独立预后生物标志物(多因素HR 2.85,95%CI 1.36-5.98,P=0.01)。总病灶活性(TLA)和代谢肿瘤体积(MTV)的下降仅在单因素分析中与OS相关,SUVmax和SUVmean变化与OS无关。

要点

  • 第2周期后SPECT/CT新发转移灶是多因素分析中OS的独立预后因素(HR 2.85,95%CI 1.36-5.98,P=0.01)。
  • TLA和MTV下降仅在单因素分析中与OS相关,多因素分析中不显著。
  • SUVmax和SUVmean变化与OS无关联。

主要发现

  • 85例患者中18例(21.2%)在第2周期SPECT/CT可见新转移灶,单因素分析HR 2.38(95%CI 1.36-4.18,P=0.002),多因素分析HR 2.85(95%CI 1.36-5.98,P=0.01)。
  • 7例(8.2%)PSA下降的患者在治疗后SPECT/CT出现新病灶。
  • TLA下降(每增加10%,HR 0.98,95%CI 0.97-1.00,P=0.016)和MTV下降(每增加10%,HR 0.98,95%CI 0.96-1.00,P=0.009)在单因素分析中与OS相关,多因素分析中不显著。
  • SUVmax和SUVmean变化与OS无关联。
  • 第1周期至第2周期PSA变化与MTV变化(相关系数0.55,95%CI 0.39-0.69,P<0.001)及TLA变化(相关系数0.56,95%CI 0.40-0.69,P<0.001)呈中度相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data are emerging on the prognostic significance of quantitative changes on posttherapy SPECT/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving [177Lu]Lu-PSMA-617. Our objective was to assess quantitative and visual changes on posttherapy SPECT/CT as prognostic biomarkers for overall survival (OS) among patients in 3 clinical trials: LuPSMA Phase 2 (ANZCTR12615000912583), LuPARP (NCT03874884), and PRINCE (NCT03658447)]. Methods: We segmented the total tumor burden on posttherapy [177Lu]Lu-PSMA-617 SPECT/CT using an SUV threshold of 3 to measure SUVmax, SUVmean, metabolic tumor volume (MTV), and total lesion activity (TLA). We assessed the prognostic value of changes in these quantitative parameters and new lesions identified visually on SPECT/CT after cycle 2 for OS using the Cox proportional hazards model, with age, Gleason score, and change in prostate-specific antigen (PSA) as covariates. Results: Eighty-five patients with mCRPC were analyzed (46 from LuPSMA Phase 2, 25 from PRINCE, and 14 from LuPARP). Patients eligible for inclusion had received at least 2 cycles of [177Lu]Lu-PSMA-617 with a follow-up time of at least 12 mo. Among these patients, 18 (21.2%) had new metastases visible on cycle 2 SPECT/CT, and this was prognostic for OS in univariate (hazard ratio [HR], 2.38; 95% CI, 1.36-4.18; P = 0.002) and multivariate (HR, 2.85; 95% CI, 1.36-5.98; P = 0.01) analyses. Seven (8.2%) patients with PSA reductions had new lesions on posttherapy SPECT/CT. Reductions in TLA (HR, 0.98; 95% CI, 0.97-1.00; P = 0.016) and MTV (HR, 0.98; 95% CI, 0.96-1.00; P = 0.009) (per 10% increase for both) were associated with OS on univariate analysis but not on multivariate analysis. Changes in SUVmax and SUVmean were not associated with OS. There was moderate correlation among changes in PSA from cycle 1 to cycle 2 and MTV (correlation coefficient = 0.55; 95% CI, 0.39-0.69; P < 0.001) and TLA (correlation coefficient = 0.56; 95% CI, 0.40-0.69; P < 0.001). Conclusion: The presence of new metastases on posttherapy SPECT/CT after cycle 2 is an independent prognostic biomarker for OS in patients with mCRPC and could guide future prospective research to improve treatment strategies for patients with poor prognoses.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kashyap R, Buteau JP, Bressel M, et al. Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025. PMID: 40610228. doi:10.2967/jnumed.125.269640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。